hrp0092p1-214 | GH and IGFs (1) | ESPE2019
, Polak Michel
, Woelfle Joachim
, Perrot Valérie
, Sert Caroline
Background: In the European Union, Increlex® (mecasermin) is approved for the treatment of growth failure in children with severe primary insulin-like growth factor-1 deficiency (SPIGFD).Methods: The European Increlex® Growth Forum Database (EU-IGFD) registry (NCT00903110) is an ongoing, multicentre, open-label, observational study monitoring the safety and efficacy of mecasermin in childr...